Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma

Medical Oncology

Volumn 29, Issue 1, 2012, Pages 134-139

  Mahipal, Amit ^a   McDonald, Mary J ^a   Witkiewicz, Agnieszka ^a   Carr, Brian I ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

EGF receptor; Invasion; Pancreatic cancer; Prognosis; Recurrence

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CELL MEMBRANE; CYTOPLASM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CELL MEMBRANE; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; HISTORY, 16TH CENTURY; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84864052249     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9802-y     Document Type: Article

References (22)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Lemoine NR, et al. The epidermal growth factor receptor in human pancreatic cancer. J Pathol. 1992;166:7-12.
3. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl 4):S9-15.
4. Kopp R, et al. Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res. 2003;162:115-32.
5. Faller BA, Burtness B. Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. Biologics. 2009;3:419-28.
6. Yamanaka Y. The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-erbB-2 oncoprotein in human pancreatic cancer. Nippon Ika Daigaku Zasshi. 1992;59:51-61.
7. Yamanaka Y, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993;13: 565-9.
8. Dong M, et al. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res. 1998;18:4613-9. (Pubitemid 29042032)
9. Uegaki K, et al. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res. 1997;17:3841-7. (Pubitemid 28014948)
10. Gansauge F, Gansauge S, Muller J, Schmid E, Beger HG. Prognostic value of molecular biology and immunologic parameters in human pancreatic carcinoma. Langenbecks Arch Chir Suppl Kongressbd. 1998;115:69-72.
11. Kuniyasu H, Abbruzzese JL, Cleary KR, Fidler IJ. Induction of ductal and stromal hyperplasia by basic fibroblast growth factor produced by human pancreatic carcinoma. Int J Oncol. 2001;19: 681-5.
12. Tobita K, et al. Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med. 2003;11:305-9.
13. Ueda S, et al. The correlation between cytoplasmic overexpres-sion of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas. 2004;29:e1-8.
14. Bloomston M, Bhardwaj A, Ellison EC, Frankel WL. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig Surg. 2006;23:74-9. (Pubitemid 44174844)
15. Takikita M, et al. Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue micro-array. Cancer Res. 2009;69:2950-5.
16. Zhang L, Yuan SZ. Expression of c-erbB-2 oncogene protein, epidermal growth factor receptor, and TGF-beta1 in human pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat Dis Int. 2002;1:620-3. (Pubitemid 36748255)
17. Piyathilake CJ, et al. Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res. 2002;8:734-44. (Pubitemid 34742102)
18. Akslen LA, Myking AO, Salvesen H, Varhaug JE. Prognostic impact of EGF-receptor in papillary thyroid carcinoma. Br J Cancer. 1993;68:808-12. (Pubitemid 23301291)
19. Bruns CJ, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000;60:2926-35. (Pubitemid 30395817)
20. Ng SS, Tsao MS, Nicklee T, Hedley DW. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther. 2002;1:777-83.
21. Moore MJ, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-6. (Pubitemid 46972777)
22. Xiong HQ, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcita-bine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2004;22:2610-6. (Pubitemid 41103748)